Shares of Bioline RX Ltd (NASDAQ:BLRX) have been given a consensus rating of “Hold” by the seven ratings firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $3.20.

Several equities research analysts have recently issued reports on the company. Oppenheimer assumed coverage on Bioline RX in a research report on Thursday, December 21st. They issued a “buy” rating and a $3.00 price target on the stock. HC Wainwright set a $4.00 price target on Bioline RX and gave the company a “buy” rating in a research report on Thursday, December 21st. Maxim Group set a $3.00 price target on Bioline RX and gave the company a “buy” rating in a research report on Monday, December 4th. ValuEngine raised Bioline RX from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 30th. Finally, Zacks Investment Research downgraded Bioline RX from a “hold” rating to a “sell” rating in a research report on Monday, November 27th.

Shares of Bioline RX (NASDAQ:BLRX) traded down $0.05 during trading hours on Monday, hitting $1.10. The stock had a trading volume of 1,060,000 shares, compared to its average volume of 651,342. The firm has a market capitalization of $121.08, a P/E ratio of -3.48 and a beta of 0.88. Bioline RX has a 12 month low of $0.80 and a 12 month high of $1.38.

WARNING: This news story was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/bioline-rx-ltd-blrx-given-consensus-recommendation-of-hold-by-brokerages/1798978.html.

Bioline RX Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Analyst Recommendations for Bioline RX (NASDAQ:BLRX)

Receive News & Ratings for Bioline RX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX and related companies with Analyst Ratings Network's FREE daily email newsletter.